Results 21 to 30 of about 800,324 (296)

Adjuvant Chemotherapy of Breast Cancer [PDF]

Breast Care, 2009
rence.’ The NCCN Practice Guidelines in Oncology Breast Cancer leave it open, intermediate and high-risk node negative patients are assigned to category 1: chemotherapy regimens comprising taxane and non-taxane containing regimens. Thus, guidelines currently do not provide real help.
Nitz, Ulrike, Cardoso, Fatima, Gnant, Michael, Thomssen, Christoph   +3 more
openaire   +3 more sources

Adjuvant chemotherapy [PDF]

Cancer, 1978
In this brief presentation, an attempt was made to illustrate why it is not possible to carry over chemotherapeutic trial results from one animal cancer to another or one human cancer to another without corrections for differences in (a) staging, (b) dose response, and (c) tumor regrowth rates.
openaire   +2 more sources

Is adjuvant chemotherapy justified in rectal cancer patients after radiochemotherapy and radical resection? [PDF]

, 2018
Recommendations for the application of post-operative adjuvant chemotherapy in patients who received preope­rative radio-chemotherapy are not consistent.
Bujko, Krzysztof
core   +1 more source

Whether Patients With Stage Ⅱ/Ⅲ Colorectal Cancer Benefit From Adjuvant Chemotherapy: A Modeling Analysis of Literature Aggregate Data

Frontiers in Pharmacology, 2022
Objective: This study used model analysis to clarify the benefits and risks of postoperative adjuvant chemotherapy compared with surgery alone in patients with stage II/III colorectal cancer.Methods: Clinical trials involving patients with stage II/III ...
Sijie Zha, Ting Li, Qingshan Zheng, Lujin Li   +3 more
doaj   +1 more source

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation [PDF]

, 2006
Objectives: To assess the clinical and cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/ leucovorin (5-FU/LV), and capecitabine monotherapy (within their licensed indications), as adjuvant therapies in the treatment of ...
Tappenden, P., P Tappenden, Sutcliffe, P., P Sutcliffe, S Paisley, S Eggington, Sutcliffe, P. (Paul), Paisley, S., Eggington, S., A Pandor, Egginton, S., Pandor, A.   +11 more
core   +1 more source

Ifosfamide with regional hyperthermia in soft-tissue sarcomas [PDF]

, 2003
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
M. Schlemmer, Wendtner, Clemens-Martin, C.M. Wendtner, R.D. Issels, Schlemmer, M., Issels, Rolf-Dieter   +5 more
core   +1 more source

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

BMC Cancer, 2018
Background There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemotherapy are unknown.
Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang, Zhen-ning Wang   +7 more
doaj   +1 more source

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer

Cancer Medicine, 2018
To identify impacts of different combined regimens of stereotactic body radiation therapy (SBRT) and chemotherapy on survival of patients with locally advanced pancreatic cancer (LAPC) and factors correlated with determinations of different combinations.
Xiaofei Zhu, Dongchen Shi, Fuqi Li, Xiaoping Ju, Yangsen Cao, Yuxin Shen, Fei Cao, Shuiwang Qing, Fang Fang, Zhen Jia, Huojun Zhang   +10 more
doaj   +1 more source

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study

BMC Cancer, 2009
Background There is currently no standard adjuvant therapy for patients with curatively resected extrahepatic biliary tract cancer (EHBTC). The aim of this study was to analyze the clinical features and outcomes between patients undergoing adjuvant ...
Kim Tae-You, Im Seock-Ah, Jang Jin-Young, Chie Eui, Oh Do-Youn, Lim Kyu-Hyoung, Kim Sun-Whe, Ha Sung, Bang Yung-Jue   +8 more
doaj   +1 more source

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial [PDF]

, 2006
Oral capecitabine (Xeloda^®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer.
F Coxon, T S Maughan, Douillard, J.Y., Lesniewski-Kmak, K, Bertetto, O., Jelic, S., Maughan, T.S., Dufour, A., J-Y Douillard, Johnston, P G, C Twelves, Díaz-Rubio, E., Cassidy, J, Twelves, C., Jelic, S, P G Johnston, Figer, A, G Fountzilas, W Scheithauer, Patel, K K, Malzyner, A, Fountzilas, G., K Lesniewski-Kmak, A Malzyner, Bustová, I, Cowell, W., Garrison, L.P., Twelves, C, Díaz-Rubio, E, O Bertetto, W Cowell, Beham, A, S Jelic, Dufour, P, J J McKendrick, Scheithauer, W., Cowell, W, Lesniewski-Kmak, K., Garrison, L P, Bustová, I., Beham, A., Fountzilas, G, A Beham, K K Patel, I Bustová, Cassidy, J., McKendrick, J.J., Bertetto, O, L P Garrison, Coxon, F., Patel, K.K., Douillard, J-Y, P Dufour, A Figer, Johnston, P.G., Scheithauer, W, Coxon, F, Maughan, T S, J Cassidy, E Díaz-Rubio, McKendrick, J J, Malzyner, A., Figer, A.   +62 more
core   +1 more source